Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 22

1.

Personalized biomarker-based treatment strategy for patients with squamous cell carcinoma of the head and neck: EORTC position and approach.

Galot R, Le Tourneau C, Guigay J, Licitra L, Tinhofer I, Kong A, Caballero C, Fortpied C, Bogaerts J, Govaerts AS, Staelens D, Raveloarivahy T, Rodegher L, Laes JF, Saada-Bouzid E, Machiels JP.

Ann Oncol. 2018 Dec 1;29(12):2313-2327. doi: 10.1093/annonc/mdy452.

2.

The clinical impact of using complex molecular profiling strategies in routine oncology practice.

Laes JF, Aftimos P, Barthelemy P, Bellmunt J, Berchem G, Camps C, Peñas RL, Finzel A, García-Foncillas J, Hervonen P, Wahid I, Joensuu T, Kathan L, Kong A, Mackay J, Mikropoulos C, Mokbel K, Mouysset JL, Odarchenko S, Perren TJ, Pienaar R, Regonesi C, Alkhayyat SS, El Kinge AR, Abulkhair O, Galal KM, Ghanem H, El Karak F, Garcia A, Ghitti G, Sadik H.

Oncotarget. 2018 Apr 17;9(29):20282-20293. doi: 10.18632/oncotarget.24757. eCollection 2018 Apr 17.

3.

Circulating tumor DNA in early response assessment and monitoring of advanced colorectal cancer treated with a multi-kinase inhibitor.

Vandeputte C, Kehagias P, El Housni H, Ameye L, Laes JF, Desmedt C, Sotiriou C, Deleporte A, Puleo F, Geboes K, Delaunoit T, Demolin G, Peeters M, D'Hondt L, Janssens J, Carrasco J, Marechal R, Galdon MG, Heimann P, Paesmans M, Flamen P, Hendlisz A.

Oncotarget. 2018 Apr 3;9(25):17756-17769. doi: 10.18632/oncotarget.24879. eCollection 2018 Apr 3.

4.

Tumor-biopsy stratification based on mTOR-pathway activity and functional mutations in the upstream genes PIK3CA and PTEN.

Laes JF, Sauvage S, Ghitti G.

Oncotarget. 2017 Sep 28;8(48):84426-84433. doi: 10.18632/oncotarget.21348. eCollection 2017 Oct 13.

5.

A Case Report Demonstrating the Potential Clinical Benefit of Exhaustive Molecular Profiling in an Aggressive Muscle-Invasive High-Grade Metastatic Urothelial Carcinoma.

Ramírez de Olano A, Bellmunt J, Rodrigo A, Álvarez L, Terrádez A, García-Foncillas J, Laes JF.

Case Rep Oncol. 2017 Jun 9;10(2):493-500. doi: 10.1159/000477337. eCollection 2017 May-Aug.

6.

The AURORA pilot study for molecular screening of patients with advanced breast cancer-a study of the breast international group.

Maetens M, Brown D, Irrthum A, Aftimos P, Viale G, Loibl S, Laes JF, Campbell PJ, Thompson A, Cortes J, Seiler S, Vinnicombe S, Oliveira M, Rothé F, Bareche Y, Fumagalli D, Zardavas D, Desmedt C, Piccart M, Loi S, Sotiriou C.

NPJ Breast Cancer. 2017 Jun 29;3:23. doi: 10.1038/s41523-017-0026-6. eCollection 2017.

7.

Plasma circulating tumor DNA as an alternative to metastatic biopsies for mutational analysis in breast cancer.

Rothé F, Laes JF, Lambrechts D, Smeets D, Vincent D, Maetens M, Fumagalli D, Michiels S, Drisis S, Moerman C, Detiffe JP, Larsimont D, Awada A, Piccart M, Sotiriou C, Ignatiadis M.

Ann Oncol. 2014 Oct;25(10):1959-65. doi: 10.1093/annonc/mdu288. Epub 2014 Jul 25.

PMID:
25185240
8.

Multi-factor data normalization enables the detection of copy number aberrations in amplicon sequencing data.

Boeva V, Popova T, Lienard M, Toffoli S, Kamal M, Le Tourneau C, Gentien D, Servant N, Gestraud P, Rio Frio T, Hupé P, Barillot E, Laes JF.

Bioinformatics. 2014 Dec 15;30(24):3443-50. doi: 10.1093/bioinformatics/btu436. Epub 2014 Jul 12.

9.

IL-12 and type I IFN response of neonatal myeloid DC to human CMV infection.

Renneson J, Dutta B, Goriely S, Danis B, Lecomte S, Laes JF, Tabi Z, Goldman M, Marchant A.

Eur J Immunol. 2009 Oct;39(10):2789-99. doi: 10.1002/eji.200939414.

10.

Evolution of microRNA expression during human bronchial squamous carcinogenesis.

Mascaux C, Laes JF, Anthoine G, Haller A, Ninane V, Burny A, Sculier JP.

Eur Respir J. 2009 Feb;33(2):352-9. doi: 10.1183/09031936.00084108. Epub 2008 Nov 14.

11.

Mutation of a potassium channel-related gene in progressive myoclonic epilepsy.

Van Bogaert P, Azizieh R, Désir J, Aeby A, De Meirleir L, Laes JF, Christiaens F, Abramowicz MJ.

Ann Neurol. 2007 Jun;61(6):579-86.

PMID:
17455289
12.

Isolation of two regions on rat chromosomes 5 and 18 affecting mammary cancer susceptibility.

Stieber D, Piessevaux G, Rivière M, Laes JF, Quan X, Szpirer J, Szpirer C.

Int J Cancer. 2007 Apr 15;120(8):1678-83.

13.

Bortezomib (PS-341, Velcade) increases the efficacy of trastuzumab (Herceptin) in HER-2-positive breast cancer cells in a synergistic manner.

Cardoso F, Durbecq V, Laes JF, Badran B, Lagneaux L, Bex F, Desmedt C, Willard-Gallo K, Ross JS, Burny A, Piccart M, Sotiriou C.

Mol Cancer Ther. 2006 Dec;5(12):3042-51. Epub 2006 Dec 5.

14.

Interferon regulatory factor 3-dependent responses to lipopolysaccharide are selectively blunted in cord blood cells.

Aksoy E, Albarani V, Nguyen M, Laes JF, Ruelle JL, De Wit D, Willems F, Goldman M, Goriely S.

Blood. 2007 Apr 1;109(7):2887-93.

15.

Genetic identification of distinct loci controlling mammary tumor multiplicity, latency, and aggressiveness in the rat.

Quan X, Laes JF, Stieber D, Rivière M, Russo J, Wedekind D, Coppieters W, Farnir F, Georges M, Szpirer J, Szpirer C.

Mamm Genome. 2006 Apr;17(4):310-21. Epub 2006 Apr 4.

PMID:
16596452
16.

Alpha-fetoprotein controls female fertility and prenatal development of the gonadotropin-releasing hormone pathway through an antiestrogenic action.

De Mees C, Laes JF, Bakker J, Smitz J, Hennuy B, Van Vooren P, Gabant P, Szpirer J, Szpirer C.

Mol Cell Biol. 2006 Mar;26(5):2012-8.

17.

Gene regulation by phorbol 12-myristate 13-acetate in MCF-7 and MDA-MB-231, two breast cancer cell lines exhibiting highly different phenotypes.

Lacroix M, Haibe-Kains B, Hennuy B, Laes JF, Lallemand F, Gonze I, Cardoso F, Piccart M, Leclercq G, Sotiriou C.

Oncol Rep. 2004 Oct;12(4):701-7.

PMID:
15375488
18.

Assignment of the rat pleiomorphic adenoma genes (Plag1, Plagl1, Plagl2) by in situ hybridization and radiation hybrid mapping.

Szpirer C, Kas K, Laes JF, Rivière M, Van Vooren P, Szpirer J.

Cytogenet Cell Genet. 2001;94(1-2):94-5. No abstract available.

PMID:
11701966
20.

Analysis of candidate genes included in the mammary cancer susceptibility 1 (Mcs1) region.

Laes JF, Quan X, Ravoet M, Stieber D, Van Vooren P, Van Reeth T, Szpirer J, Szpirer C.

Mamm Genome. 2001 Mar;12(3):199-206.

PMID:
11252168
21.

Localization of new, microdissection- generated, anonymous markers and of the genes Pcsk1, Dhfr, Ndub13, and Ccnb1 to rat chromosome region 2q1.

Quan X, Laes JF, Ravoet M, Van Vooren P, Szpirer J, Szpirer C.

Cytogenet Cell Genet. 2000;88(1-2):119-23.

PMID:
10773684

Supplemental Content

Support Center